22 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 02:14
  [Comment] Biodiversity and its double-edged role in the pathogenesis of type 1 diabetes - Daniel Chan, Jan Hau Lee Lancet Diab Endocrinol
  Over the past decade, research into the mechanistic pathways and causal factors of type 1 diabetes has revealed increasing complexity in its pathogenesis. The immune system is a key mediator between the genomics of an individual who is susceptible to type 1 diabetes and the immediate (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 02:14
  [Correspondence] Long-term association between homelessness and mortality among people with diabetes - Kathryn Wiens, Li Bai, Peter C Austin, Paul E Ronksley, Stephen W Hwang, Eldon Spackman, Gillian L Booth, David J T Campbell Lancet Diab Endocrinol
  People experiencing homelessness with diabetes face many barriers to care and self-management, including a lack of control over meal options or eating schedules, not having a safe place to store medications, and difficulties navigating the health-care system.1 Consequently, such situations put (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 02:14
  [Corrections] Correction to Lancet Diabetes Endocrinol 2020; 8: 490–500 Lancet Diab Endocrinol
  Ferrara A, Hedderson MM, Brown SD, et al. A telehealth lifestyle intervention to reduce excess gestational weight gain in pregnant women with overweight or obesity (GLOW): a randomised, parallel-group, controlled trial. Lancet Diabetes Endocrinol 2020; 8: 490–500—The appendix of this Article has (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 02:14
  [Articles] SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study - Mikael Knip, Anna Parviainen, Maaret Turtinen, Anna But, Taina Härkönen, Jussi Hepojoki, Tarja Sironen, Rommel Iheozor-Ejiofor, Hasan U?urlu, Kalle Saksela, Johanna Lempainen, Jorma Ilonen, Olli Vapalahti, Finnish Pediatric Diabetes Register Lancet Diab Endocrinol
  Children and adolescents diagnosed with type 1 diabetes during the pandemic had a more severe disease at diagnosis. The observed increase in type 1 diabetes incidence during the first 18 months could be a consequence of lockdown and physical distancing rather than a direct effect of SARS-CoV-2 (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))

4 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Let's talk about obesity - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Obesity is a topic frequently discussed and debated in news, social media, and popular culture. From reports linking obesity to various social factors to endless articles and posts promoting weight loss, stigma around obesity and felt by people with obesity can be (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 00:30
  [Comment] Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity - Francesco Rubino, Rachel L Batterham, Marta Koch, Geltrude Mingrone, Carel W le Roux, I Sadaf Farooqi, Nathalie Farpour-Lambert, Edward W Gregg, David E Cummings Lancet Diab Endocrinol
  Obesity was first recognised as a disease by WHO in 1948, then between 2013 and 2022 by several medical societies and countries.1–8 However, the notion that obesity is a disease and not merely a risk factor for other illnesses remains highly controversial, both within and beyond medical circles. (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 00:30
  [Articles] Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial - Meir Schechter, Stephen D Wiviott, Itamar Raz, Erica L Goodrich, Aliza Rozenberg, Ilan Yanuv, Sabina A Murphy, Thomas A Zelniker, Martin Fredriksson, Peter A Johansson, Lawrence A Leiter, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Avivit Cahn, Anna Maria Langkilde, Marc S Sabatine, Ofri Mosenzon Lancet Diab Endocrinol
  Dapagliflozin reduced the risk of first and total non-elective hospitalisations for any cause in people with type 2 diabetes, regardless of the presence of atherosclerotic cardiovascular disease, including hospitalisations not directly attributed to cardiac, kidney, or metabolic causes. These (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 00:30
  [Comment] The growing clinical effect of SGLT2 inhibitors - Stefano Del Prato Lancet Diab Endocrinol
  In September, 2015, the results of EMPA-REG OUTCOME, the first cardiovascular outcomes study based on a sodium-glucose co-transporter-2 (SGLT2) inhibitor, empagliflozin, were announced at the Annual Meeting of the European Association for the Study of Diabetes. It was the first of a series of (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))

3 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Rossella Nappi: taking the stigma out of menopause - Talha Burki Lancet Diab Endocrinol
  A few years ago, Rossella Nappi was scheduled to speak at a conference for obstetricians and gynaecologists. “A lot of people were waiting and I was in a rush, as usual”, recalled Nappi, who is professor of obstetrics and gynaecology at the University of Pavia (Pavia, Lombardy, Italy) and chief (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))

1 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] SEARCHing for answers to youth-onset type 2 diabetes - Jonathan E Shaw, Dianna J Magliano Lancet Diab Endocrinol
  Until recent decades, youth-onset diabetes was almost entirely type 1 diabetes, but the emergence of type 2 diabetes at younger and younger ages, primarily as a result of increasing obesity, has significantly changed this.1 (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 00:30
  [Articles] Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study - Lynne E Wagenknecht, Jean M Lawrence, Scott Isom, Elizabeth T Jensen, Dana Dabelea, Angela D Liese, Lawrence M Dolan, Amy S Shah, Anna Bellatorre, Katherine Sauder, Santica Marcovina, Kristi Reynolds, Catherine Pihoker, Giuseppina Imperatore, Jasmin Divers, SEARCH for Diabetes in Youth study Lancet Diab Endocrinol
  The increasing incidence of type 1 and type 2 diabetes in children and young people in the USA will result in an expanding population of young adults at risk of developing early complications of diabetes whose health-care needs will exceed those of their peers. Findings regarding age and season (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))

25 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Mechanisms of ageing: growth hormone, dietary restriction, and metformin - Jansher Khan, Ida Pernicova, Kiran Nisar, Márta Korbonits Lancet Diab Endocrinol
  Tackling the mechanisms underlying ageing is desirable to help to extend the duration and improve the quality of life. Life extension has been achieved in animal models by suppressing the growth hormone–insulin-like growth factor 1 (IGF-1) axis and also via dietary restriction. Metformin has (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))
• 00:30
  [Review] Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis - Wilmar M Wiersinga, Kris G Poppe, Grigoris Effraimidis Lancet Diab Endocrinol
  Hyperthyroidism is a common condition with a global prevalence of 0·2–1·3%. When clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg, low TSH, high free thyroxine [FT4], or high free tri-iodothyonine [FT3]). If hyperthyroidism is confirmed by biochemical (...) (The Lancet Diabetes & Endocrinology 11, 4 (2023))

22 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 01:31
  [Editorial] Rare diseases: individually rare, collectively common - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Rare Disease Day is celebrated on Feb 28 each year (or Feb 29 in leap years—the rarest day). It serves as a focal point to raise awareness about rare diseases, the challenges faced by people living with a rare disease, their families, and caregivers, and to advocate for equity in access to (...) (The Lancet Diabetes & Endocrinology 11, 3 (2023))
• 01:31
  [Comment] Beyond genetic screening—functionality-based precision medicine in monogenic obesity - Antje Körner, Robert Stein, Kathrin Landgraf Lancet Diab Endocrinol
  The availability of sophisticated genomic screening approaches has revealed numerous genes and genetic variants associated with common and rare disease phenotypes, including obesity (BMI ?30 kg/m2). Most genes causing monogenic obesity are implicated in the central energy regulatory circuits of (...) (The Lancet Diabetes & Endocrinology 11, 3 (2023))
• 01:31
  [Comment] Can non-equilibrium thermodynamics explain skeletal muscle insulin resistance due to low mitochondrial content? - Lawrence J Mandarino, Wayne T Willis Lancet Diab Endocrinol
  Insulin resistance plays a crucial part in the development of type 2 diabetes and metabolic syndrome. A defect in insulin secretion characterises the natural history of hyperglycaemia and type 2 diabetes,1 usually occurring in the context of insulin resistance. Insulin resistance is present in (...) (The Lancet Diabetes & Endocrinology 11, 3 (2023))
• 01:31
  [Comment] New indications for metabolic and bariatric surgery - Anita P Courcoulas Lancet Diab Endocrinol
  A 2022 joint statement from the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders summarises the most current literature and updates the indications for metabolic and bariatric surgical procedures.1 This is a (...) (The Lancet Diabetes & Endocrinology 11, 3 (2023))
• 01:31
  [Comment] Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2022 - The Lancet Diabetes & Endocrinology Editors Lancet Diab Endocrinol
  Syed Faisal Ahmed (The Lancet Diabetes & Endocrinology 11, 3 (2023))
• 01:31
  [Articles] Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study - Lise Folon, Morgane Baron, Bénédicte Toussaint, Emmanuel Vaillant, Mathilde Boissel, Victoria Scherrer, Hélène Loiselle, Audrey Leloire, Alaa Badreddine, Beverley Balkau, Guillaume Charpentier, Sylvia Franc, Michel Marre, Soulaimane Aboulouard, Michel Salzet, Mickaël Canouil, Mehdi Derhourhi, Philippe Froguel, Amélie Bonnefond Lancet Diab Endocrinol
  Only carriers of heterozygous, null, or complete loss-of-function PCSK1 variants cause monogenic obesity and, therefore, might be eligible for setmelanotide. In silico tests were unable to accurately detect these variants, which suggests that in vitro assays are necessary to determine the (...) (The Lancet Diabetes & Endocrinology 11, 3 (2023))